4.7 Article

CRMP2 as a Candidate Target to Interfere with Lung Cancer Cell Migration

期刊

BIOMOLECULES
卷 11, 期 10, 页码 -

出版社

MDPI
DOI: 10.3390/biom11101533

关键词

CRMP2; lung cancer; migration; cytoskeleton

资金

  1. MIMECO [DPI2012-38090-C03-02]
  2. Basque Country government
  3. MIMECO/Torres Quevedo program [PTQ-11-04778]
  4. Spanish Ministry of Science, Innovation and Universities [RTI2018-094494-B-C22]

向作者/读者索取更多资源

CRMP2 is an adaptor protein involved in cytoskeleton molding and has been found to play a crucial role in cancer progression. Phosphorylation of CRMP2 affects cancer cell migration, leading to impaired tumor growth in related mutants.
Collapsin response mediator protein 2 (CRMP2) is an adaptor protein that adds tubulin dimers to the growing tip of a microtubule. First described in neurons, it is now considered a ubiquitous protein that intervenes in processes such as cytoskeletal remodeling, synaptic connection and trafficking of voltage channels. Mounting evidence supports that CRMP2 plays an essential role in neuropathology and, more recently, in cancer. We have previously described a positive correlation between nuclear phosphorylation of CRMP2 and poor prognosis in lung adenocarcinoma patients. In this work, we studied whether this cytoskeleton molding protein is involved in cancer cell migration. To this aim, we evaluated CRMP2 phosphorylation and localization in the extending lamella of lung adenocarcinoma migrating cells using in vitro assays and in vivo confocal microscopy. We demonstrated that constitutive phosphorylation of CRMP2 impaired lamella formation, cell adhesion and oriented migration. In search of a mechanistic explanation of this phenomenon, we discovered that CRMP2 Ser522 phospho-mimetic mutants display unstable tubulin polymers, unable to bind EB1 plus-Tip protein and the cortical actin adaptor IQGAP1. In addition, integrin recycling is defective and invasive structures are less evident in these mutants. Significantly, mouse xenograft tumors of NSCLC expressing CRMP2 phosphorylation mimetic mutants grew significantly less than wild-type tumors. Given the recent development of small molecule inhibitors of CRMP2 phosphorylation to treat neurodegenerative diseases, our results open the door for their use in cancer treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据